HIV Infection Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled, Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ABBV-181 in HIV-1 Infected Adults
Verified date | March 2023 |
Source | AbbVie |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will be conducted in two stages and will test the safety/tolerability, pharmacokinetics (how the body handles study drug) and pharmacodynamics (effects on the immune system and the virus) of the study drug ABBV-181 in Human immunodeficiency virus (HIV)-1 infected participants undergoing Antiretroviral therapy (ART) interruption.
Status | Completed |
Enrollment | 41 |
Est. completion date | February 27, 2023 |
Est. primary completion date | February 27, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Body Mass Index (BMI) between 18.0 and 35 kg/m2. - HIV-1 infected on antiretroviral therapy (ART) for at least 12 months prior to screening and on current ART regimen for at least 8 weeks prior to screening. - Meets HIV-specific laboratory parameters as below: - Plasma HIV-1 RNA below lower limit of quantification (LLOQ) at screening and at least 6 months prior to screening. - CD4+ T cell count >= 500 cells/uL at screening and at least once during the 12 months prior to screening. - CD4+ T cell nadir of >= 200 cells/uL during chronic infection. - Willing to undergo ART interruption. - Agrees to use an effective barrier method of protection (male and/or female condoms) during sexual activity for protection against HIV-1 transmission throughout the entire study. Exclusion Criteria: - Known resistance to at least 2 classes of ART. - History of AIDS-defining illness. - Active or suspected malignancy or history of malignancy (other than basal cell skin cancer or cervical carcinoma in situ) in the past 5 years. - History of or active immunodeficiency (other than HIV). - Active autoimmune disease or history of autoimmune disease that has required systemic treatment. - Prior receipt of immunomodulatory or immunosuppressive (including intravenous infusion or oral steroids at any dose, but excluding steroids that are inhaled, topical or by local injection) therapy within 24 weeks prior to the first dose of study drug. - Prior therapy/exposure to ABBV-181 or any other immune checkpoint inhibitor. - Current hepatitis B virus or hepatitis C virus infection. - Clinically significant medical disorders that might expose the participants to undue risk of harm, confound study outcomes, or prevent the participant from completing the study (including but not limited to significant or unstable cardiac, neurologic or pulmonary disease, chronic active infectious disease except for HIV, chronic liver disease, poorly controlled diabetes mellitus and history of Stevens Johnson Syndrome toxic epidermal necrolysis (TEN), or drug reaction with eosinophilia and systemic symptoms (DRESS)). - Known psychiatric or substance abuse disorders that would interfere with adherence to study requirements. - Female participants must not be pregnant, breastfeeding, or considering becoming pregnant during the study. |
Country | Name | City | State |
---|---|---|---|
Australia | Holdsworth House Medical Practice /ID# 215352 | Darlinghurst | New South Wales |
Australia | St Vincent's Hospital Sydney /ID# 215354 | Darlinghurst | New South Wales |
Australia | The Royal Melbourne Hospital /ID# 215351 | Parkville | Victoria |
Canada | McGill Univ Clinical Research /ID# 218081 | Montreal | Quebec |
Canada | Ottawa Hospital Research Institute /ID# 218083 | Ottawa | Ontario |
Canada | Toronto General Hospital /ID# 218082 | Toronto | Ontario |
Puerto Rico | Clinical Research Puerto Rico /ID# 218821 | San Juan | |
Puerto Rico | Puerto Rico AIDS Clinical Trials Unit CRS /ID# 213761 | San Juan | |
United States | Franco Felizarta, Md /Id# 215721 | Bakersfield | California |
United States | Be Well Medical Center /ID# 223841 | Berkley | Michigan |
United States | University of Cincinnati /ID# 215615 | Cincinnati | Ohio |
United States | North TX Infectious Diseases /ID# 224861 | Dallas | Texas |
United States | Prism Health North Texas - Oak Cliff Health Center /ID# 214036 | Dallas | Texas |
United States | Midway Immunology and Research /ID# 215587 | Fort Pierce | Florida |
United States | Ruane Clinical Research Group /ID# 224866 | Los Angeles | California |
United States | University of Miami, Miller School of Medicine /ID# 213833 | Miami | Florida |
United States | Saint Michael's Medical Center /ID# 228733 | Newark | New Jersey |
United States | Orlando Immunology Center /ID# 243276 | Orlando | Florida |
United States | Mayo Clinic - Rochester /ID# 217820 | Rochester | Minnesota |
United States | Quest Clinical Research /ID# 215796 | San Francisco | California |
United States | Peter Shalit, M.D. /ID# 224870 | Seattle | Washington |
United States | George Washington University Medical Faculty Associates /ID# 213893 | Washington | District of Columbia |
United States | Triple O Research Institute /ID# 224863 | West Palm Beach | Florida |
Lead Sponsor | Collaborator |
---|---|
AbbVie |
United States, Australia, Canada, Puerto Rico,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants with Study Drug-Related Adverse Events Grade 3 or Higher | An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of the study drug as either having a reasonable possibility or no reasonable possibility. AEs are given a grade from 1-5 with Grade 3 being severe but not life-threatening and requiring hospitalization, Grade 4 being life-threatening requiring immediate intervention and Grade 5 being death related to an AE. | Up to approximately 44 weeks | |
Primary | Number of Participants with Study Drug-Related Immune-Related Adverse Events (IRAE) | Assessed using the American Society of Clinical Oncology (ASCO) IRAE management guidelines (which utilizes the NIH CTCAE grading scale) but modified, as applicable, according to the NIH Division of AIDS (DAIDS) (v2.1) AE grading scale. | Up to approximately 44 weeks | |
Primary | Number of Participants with Adverse Events (AEs) Corresponding to Retroviral Rebound Syndrome | Adverse Events (AEs) Corresponding to Retroviral Rebound Syndrome. | Up to approximately 44 weeks | |
Primary | Maximum Observed Concentration (Cmax) | Maximum Observed Concentration (Cmax) of ABBV-181. | Up to approximately 36 weeks | |
Primary | Time to Cmax (Tmax) | Time to Cmax (Tmax) of ABBV-181. | Up to approximately 36 weeks | |
Primary | Observed Concentration (Ctrough) | Observed Concentration (Ctrough) at the end of the dosing intervals for ABBV-181. | Up to approximately 36 weeks | |
Primary | Area Under the Curve (AUCtau) | Area Under the Curve (AUCtau) during the dosing intervals for ABBV-181. | Up to approximately 36 weeks | |
Primary | Half-life (t1/2) | Half-life (t1/2) of ABBV-181 following the last dose. | Up to approximately 36 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02135419 -
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
|
Phase 3 | |
Active, not recruiting |
NCT02663856 -
My Smart Age With HIV: Smartphone Self-assessment of Frailty
|
||
Completed |
NCT02663869 -
Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
|
||
Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 | |
Completed |
NCT02921516 -
Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings
|
N/A | |
Completed |
NCT02659306 -
Metformin Immunotherapy in HIV Infection
|
Phase 1 | |
Completed |
NCT02846402 -
Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda
|
N/A | |
Completed |
NCT02564341 -
Targeting Effective Analgesia in Clinics for HIV - Intervention
|
N/A | |
Active, not recruiting |
NCT02302950 -
A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
|
N/A | |
Completed |
NCT02269605 -
Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment
|
Phase 1 | |
Completed |
NCT01830595 -
Lactoferrin Treatment in HIV Patients
|
Phase 2 | |
Completed |
NCT01852942 -
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
|
Phase 2 | |
Terminated |
NCT02109224 -
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
|
Phase 1 | |
Terminated |
NCT01902186 -
Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir
|
Phase 4 | |
Completed |
NCT02118168 -
Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002
|
N/A | |
Completed |
NCT02525146 -
Birmingham Access to Care Study
|
N/A | |
Completed |
NCT01946217 -
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
|
N/A | |
Completed |
NCT02527135 -
Text Messaging to Improve HIV Testing Among Young Women in Kenya
|
N/A | |
Active, not recruiting |
NCT02602418 -
Neural Correlates of Working Memory Training for HIV Patients
|
N/A | |
Completed |
NCT01680094 -
Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART
|
Phase 1/Phase 2 |